193902-64-6 Usage
Uses
Used in Pharmaceutical Industry:
1-BOC-4-(4-AMINO-PHENYL)-PIPERAZINE DIHYDROCHLORIDE is used as a key intermediate for the synthesis of various pharmaceuticals, leveraging its potential antineoplastic and antitumor activities. Its BOC protecting group allows for the controlled deprotection of amines, facilitating the development of new drugs with targeted therapeutic benefits.
Used in Research and Development:
In the research industry, 1-BOC-4-(4-AMINO-PHENYL)-PIPERAZINE DIHYDROCHLORIDE is utilized for the exploration and development of novel compounds with potential therapeutic applications. Its unique structure and functional groups make it a valuable tool in medicinal chemistry for creating new drug candidates and understanding their mechanisms of action.
Used in Organic Synthesis:
1-BOC-4-(4-AMINO-PHENYL)-PIPERAZINE DIHYDROCHLORIDE is employed as a protected amine in organic synthesis, where the BOC group is strategically used to prevent unwanted side reactions. This allows chemists to carry out complex synthetic routes with greater control over the reaction conditions and outcomes, ultimately leading to the production of desired organic compounds with specific properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 193902-64-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,9,0 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 193902-64:
(8*1)+(7*9)+(6*3)+(5*9)+(4*0)+(3*2)+(2*6)+(1*4)=156
156 % 10 = 6
So 193902-64-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H23N3O2.2ClH/c1-15(2,3)20-14(19)18-10-8-17(9-11-18)13-6-4-12(16)5-7-13;;/h4-7H,8-11,16H2,1-3H3;2*1H
193902-64-6Relevant articles and documents
Fibrinogen receptor antagonists
-
, (2008/06/13)
This invention relates to compounds of the formula: which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.